PL4320102T3 - Związki pirydazyny do inhibicji nlrp3 - Google Patents

Związki pirydazyny do inhibicji nlrp3

Info

Publication number
PL4320102T3
PL4320102T3 PL22719717.5T PL22719717T PL4320102T3 PL 4320102 T3 PL4320102 T3 PL 4320102T3 PL 22719717 T PL22719717 T PL 22719717T PL 4320102 T3 PL4320102 T3 PL 4320102T3
Authority
PL
Poland
Prior art keywords
pyridazine compounds
inhibiting nlrp3
nlrp3
inhibiting
pyridazine
Prior art date
Application number
PL22719717.5T
Other languages
English (en)
Inventor
Stéphane DORICH
Jason Burch
Miguel St-Onge
Amandine Chefson
Alexandre Côté
Ramsay Beveridge
Stéphane CIBLAT
Original Assignee
Ventus Therapeutics U.S., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U.S., Inc. filed Critical Ventus Therapeutics U.S., Inc.
Publication of PL4320102T3 publication Critical patent/PL4320102T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL22719717.5T 2021-04-07 2022-04-07 Związki pirydazyny do inhibicji nlrp3 PL4320102T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171932P 2021-04-07 2021-04-07
US17/528,928 US11319319B1 (en) 2021-04-07 2021-11-17 Compounds for inhibiting NLRP3 and uses thereof
PCT/US2022/023893 WO2022216971A1 (en) 2021-04-07 2022-04-07 Pyridazine compounds for inhibiting nlrp3

Publications (1)

Publication Number Publication Date
PL4320102T3 true PL4320102T3 (pl) 2026-04-13

Family

ID=81385286

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22719717.5T PL4320102T3 (pl) 2021-04-07 2022-04-07 Związki pirydazyny do inhibicji nlrp3

Country Status (22)

Country Link
US (12) US11319319B1 (pl)
EP (3) EP4320102B1 (pl)
JP (2) JP7620120B2 (pl)
KR (1) KR20230167394A (pl)
CN (2) CN117500792A (pl)
AU (3) AU2022256052B2 (pl)
BR (1) BR112023020483A2 (pl)
CA (1) CA3214676A1 (pl)
CL (2) CL2023002973A1 (pl)
CO (1) CO2023013356A2 (pl)
ES (1) ES3064060T3 (pl)
HR (1) HRP20260190T1 (pl)
IL (2) IL307303A (pl)
JO (1) JOP20230241A1 (pl)
MA (1) MA64053B1 (pl)
MX (2) MX2023011576A (pl)
PE (1) PE20240765A1 (pl)
PL (1) PL4320102T3 (pl)
RS (1) RS67854B1 (pl)
TW (2) TWI909104B (pl)
UA (1) UA130929C2 (pl)
WO (1) WO2022216971A1 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CN115433163A (zh) * 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
PL4363406T3 (pl) * 2021-07-02 2026-01-05 Astrazeneca Ab Inhibitory inflamasomu nlrp3
CA3226995A1 (en) 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) * 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
KR20250005125A (ko) * 2022-03-25 2025-01-09 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
EP4499646A4 (en) * 2022-03-31 2026-03-18 Hangzhou Highlightll Pharmaceutical Co Ltd NLRP3 Inflammasome Inhibitors
JP2025524640A (ja) * 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CN116789674B (zh) * 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
CN119907797A (zh) * 2022-09-23 2025-04-29 默沙东有限责任公司 用作nod样受体蛋白3抑制剂的酞嗪衍生物
JP7863148B2 (ja) * 2022-09-23 2026-05-20 メルク・シャープ・アンド・ドーム・エルエルシー Ｎｏｄ様受容体タンパク質３の阻害剤として有用なフタラジン誘導体
CN120152974A (zh) 2022-10-26 2025-06-13 天维生物制药有限公司 缩环哒嗪衍生物
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
EP4612150A1 (en) * 2022-10-31 2025-09-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
US20260167637A1 (en) * 2022-11-04 2026-06-18 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
WO2024109922A1 (zh) * 2022-11-25 2024-05-30 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
EP4637746A1 (en) * 2022-12-19 2025-10-29 Merck Sharp & Dohme LLC 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
US20260200914A1 (en) 2022-12-28 2026-07-16 Astrazeneca Ab Nlrp3 inflammasome inhibitors
KR20250162767A (ko) 2022-12-28 2025-11-19 아스트라제네카 아베 Nlrp3 인플라마좀 억제제의 결정질 형태, 화학 공정 및 화학적 화합물
CN120418236A (zh) * 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
CN120569372A (zh) 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
EP4658649A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV [1,2,4]triazolo[4,3-a]pyridines and [1,2,4]triazolo[4,3-a]pyrazines as nlrp3 inhibitors
JP2026504422A (ja) 2023-01-31 2026-02-05 ヤンセン ファーマシューティカ エヌ．ベー． ＮＬＲＰ３阻害剤としてのピロロ［１，２－ｄ］［１，２，４］トリアジン及びピラゾロ［１，５－ｄ］［１，２，４］トリアジン
EP4658644A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV 2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors
WO2024160693A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
WO2024160692A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
WO2024169858A1 (zh) * 2023-02-17 2024-08-22 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途
WO2024217462A1 (zh) * 2023-04-18 2024-10-24 南京明德新药研发有限公司 五氟化硫取代的芳环化合物及其应用
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
WO2025006681A2 (en) * 2023-06-27 2025-01-02 Viva Star Biosciences (Us) Inc. Substituted pyridazine compounds as inhibitors of nlrp3 activity and therapeutic uses thereof
CR20260091A (es) * 2023-08-11 2026-05-05 Neurocrine Biosciences Inc Inhibidor del inflamasoma nlrp3 y su uso
CN117143027B (zh) * 2023-08-31 2024-12-20 四川大学 3-苄氧基-6-羟苯基哒嗪类化合物及其制备方法和用途
EP4777504A1 (en) * 2023-09-12 2026-07-22 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025059481A1 (en) * 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
KR20250074627A (ko) 2023-11-20 2025-05-27 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3을 억제하기 위한 5-클로로-2-(4-((2-하이드록시-2-메틸프로필)아미노)피리도[3,4-d]피리다진-1-일)페놀의 고형 유리염기 형태 및 이의 용도
US20250223290A1 (en) 2023-12-14 2025-07-10 Merck Sharp & Dohme Llc Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
TW202535370A (zh) 2023-12-14 2025-09-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之吲唑衍生物
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2026002217A1 (zh) * 2024-06-28 2026-01-02 长春金赛药业有限责任公司 Nlrp3抑制剂的多晶型物及其制备方法和应用
WO2026002229A1 (zh) * 2024-06-28 2026-01-02 长春金赛药业有限责任公司 一种nlrp3抑制剂化合物及其制备方法和应用
WO2026067767A1 (zh) * 2024-09-30 2026-04-02 普罗思特(南京)生物科技有限公司 取代的哒嗪衍生物及其应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB1303061A (pl) * 1969-05-03 1973-01-17
GB2063249A (en) * 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
JPH03284669A (ja) * 1990-03-30 1991-12-16 Mitsubishi Kasei Corp ４―フェニルフタラジン誘導体
ES2068413T3 (es) 1990-03-30 1995-04-16 Mitsubishi Chem Ind Derivados de 4-fenilftalazina.
TW279162B (pl) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
ATE175196T1 (de) 1992-01-23 1999-01-15 Pfizer 4-phenyl-3-(heteroarylureido)-1,2-dihydro-2- oxochinolin derivate, als antihypercholesterolemische und antiatherosklerotische mittel
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
DE4417746A1 (de) 1994-05-20 1995-11-23 Bayer Ag Neue Farbstoffe zum Massefärben von Kunststoffen
EP0722936B1 (en) * 1994-08-09 2004-05-19 Eisai Co., Ltd. Fused pyridazine compound
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
KR100485249B1 (ko) * 1996-08-20 2005-09-09 에자이 가부시키가이샤 축합피리다진계화합물의발기기능부전증치료제
US20030124053A1 (en) 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
JP2001506653A (ja) 1996-12-18 2001-05-22 ニューロゲン コーポレイション Ｃｒｆレセプターと相互作用するイソキノリナミン及びフタルアジナミン誘導体
US6486158B1 (en) 1998-08-14 2002-11-26 Cell Pathways, Inc. [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
CA2368023A1 (en) 1999-03-22 2000-09-28 Guixue Yu Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
ATE405574T1 (de) 2001-11-30 2008-09-15 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
US20040242886A1 (en) 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
WO2005016000A1 (en) 2003-08-05 2005-02-24 Avalon Pharmaceuticals Derivatives of cyclic quinone and uses thereof
US7087621B2 (en) 2003-09-05 2006-08-08 Bristol-Myers Squibb Company Benzo- and azabenzodithiazole compounds
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
EP1745039A4 (en) * 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2005121157A1 (en) 2004-06-09 2005-12-22 Sumitomo Chemical Company, Limited Monophosphine compounds, transition metal complexes thereof and production of optically active compounds using the complexes as asymmetric catalysts
US20060156485A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
CN101312968A (zh) 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
FR2891828B1 (fr) 2005-10-12 2007-12-21 Sanofi Aventis Sa Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
JP2009514883A (ja) 2005-11-03 2009-04-09 イリプサ， インコーポレイテッド アザインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
WO2007056580A2 (en) 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
JP2009120486A (ja) * 2005-12-05 2009-06-04 Mitsubishi Pharma Corp 核内オーファン受容体の新規活性化剤及びその用途
EA018128B1 (ru) 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EP1984354B1 (en) 2006-02-16 2009-08-05 Syngeta Participations AG Pesticides containing a bicyclic bisamide structure
AU2007283401A1 (en) 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
CA2685219C (en) 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US9023490B2 (en) 2007-06-15 2015-05-05 Versitech Limited Extended pi-conjugated platinum (II) complexes
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
US20090082358A1 (en) 2007-09-20 2009-03-26 Nobuko Nishimura Vanilloid receptor ligands and their use in treatments
EP2234618A4 (en) 2007-12-21 2011-04-27 Scripps Research Inst BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US8445473B2 (en) 2008-04-11 2013-05-21 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
JP2011520890A (ja) 2008-05-15 2011-07-21 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
NZ590503A (en) 2008-06-16 2012-08-31 Merck Patent Gmbh Quinoxalinedione derivatives
CN102076653A (zh) 2008-06-25 2011-05-25 住友化学株式会社 用于制备光学活性胺化合物的方法
JP2012500272A (ja) 2008-08-16 2012-01-05 ジェネンテック， インコーポレイテッド Ｉａｐのアザインドールインヒビター
US20110178117A1 (en) 2008-09-26 2011-07-21 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
CA2754058A1 (en) 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2414353A1 (en) 2009-04-01 2012-02-08 Basf Se Isoxazoline compounds for combating invertebrate pests
WO2010117936A1 (en) 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
US9593108B2 (en) 2009-04-06 2017-03-14 Ptc Therapeutics, Inc. Compounds and methods for antiviral treatment
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP5826261B2 (ja) 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
AU2011271462A1 (en) 2010-06-30 2013-01-10 Amgen Inc. Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors
EP2616443A1 (en) 2010-09-14 2013-07-24 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
MX2013013211A (es) 2011-05-18 2014-02-20 Syngenta Participations Ag Compuestos insecticidas a base de derivados de ariltioacetamida.
WO2013020622A1 (en) 2011-08-08 2013-02-14 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
BR112014003971A2 (pt) 2011-08-25 2017-03-21 Syngenta Participations Ag métodos para o controle de cupins e formigas
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
JP5976206B2 (ja) 2012-05-22 2016-08-23 イーライ リリー アンド カンパニー 神経機能障害を検出するための造影剤
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014079935A1 (en) 2012-11-21 2014-05-30 Syngenta Participations Ag Insecticidal compounds based on arylthioacetamide derivatives
WO2014079941A1 (en) 2012-11-21 2014-05-30 Syngenta Participations Ag Insecticidal compounds based on n-(arylsulfanylmethyl) carboxamide derivatives
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014086737A1 (de) 2012-12-06 2014-06-12 Bayer Cropscience Ag Kondensierte 2-pyridon-3-carboxamide und ihre verwendung als herbizide
TW201439060A (zh) 2013-02-27 2014-10-16 Sunshine Lake Pharma Co Ltd 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
AR097631A1 (es) 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
CN103992311B (zh) * 2014-06-20 2017-01-25 东南大学 Hedgehog信号通路抑制剂
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
RU2741387C2 (ru) 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
US20180093956A1 (en) 2015-02-06 2018-04-05 Abbvie Inc. Substituted phthalazines
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
SG11201806700RA (en) 2016-02-12 2018-09-27 Pharmaxis Ltd Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3236267B1 (en) 2016-04-18 2021-09-08 Roche Diagnostics GmbH Decapper and apparatus
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
WO2018031680A1 (en) 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
KR102507847B1 (ko) * 2016-10-28 2023-03-08 서울대학교병원 페닐 프탈라진 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
WO2018172925A1 (en) 2017-03-23 2018-09-27 Vitas Pharma Research Pvt Ltd Inhibitors of dna gyrase for treatment of bacterial infections
KR20180108426A (ko) 2017-03-24 2018-10-04 희성소재 (주) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2018174678A1 (ko) 2017-03-24 2018-09-27 희성소재(주) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
WO2018221433A1 (ja) 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
JP6849248B2 (ja) 2017-07-20 2021-03-24 エルジー・ケム・リミテッド 化合物およびこれを含む有機発光素子
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
KR20200043433A (ko) 2017-08-21 2020-04-27 메르크 파텐트 게엠베하 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
WO2020021015A1 (en) 2018-07-26 2020-01-30 Esteve Pharmaceuticals, S.A. New imidazopyridine derivatives for treating pain and pain related conditions
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102721075B1 (ko) 2019-02-15 2024-10-24 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN115279739B (zh) * 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
KR20230016658A (ko) 2020-05-28 2023-02-02 얀센 파마슈티카 엔.브이. 화합물
GB2595975B (en) 2020-06-09 2022-12-07 Pardes Biosciences Inc Inhibitors of cysteine proteases and methods of use thereof
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
AU2022254062A1 (en) 2021-04-07 2023-10-12 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 1 (usp1)
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
CA3212725A1 (en) 2021-04-29 2022-11-03 Daniel Oehlrich Phthalazinone derivatives as nlrp3 inflammasome inhibitors
LT4337652T (lt) 2021-05-12 2025-06-25 F. Hoffmann-La Roche Ag Nlrp3 inhibitoriai
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CN115433163A (zh) 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
JP2024529839A (ja) 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
PL4363406T3 (pl) 2021-07-02 2026-01-05 Astrazeneca Ab Inhibitory inflamasomu nlrp3
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
CA3226995A1 (en) 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
IL310992A (en) 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
CN117858871A (zh) 2021-08-25 2024-04-09 兹杜斯生命科学有限公司 用于神经炎性病症的治疗
WO2023051761A1 (zh) 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
IL310442A (en) 2021-10-19 2024-03-01 Hoffmann La Roche FUSED BICYCLIC heteroaryl compounds are useful as NLRP3 inhibitors
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
CN118234730A (zh) 2021-11-17 2024-06-21 豪夫迈·罗氏有限公司 杂环nlrp3抑制剂
JP2024540525A (ja) 2021-11-19 2024-10-31 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３の阻害剤としてのピリダジン誘導体
WO2023129987A1 (en) 2021-12-29 2023-07-06 Neumora Therapeutics, Inc. Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
MX2024008548A (es) 2022-01-07 2024-07-19 Transthera Sciences Nanjing Inc Inhibidor del inflamosoma nlrp3 y uso del mismo.
CN116726020A (zh) 2022-03-08 2023-09-12 上海拓界生物医药科技有限公司 一类含哒嗪的化合物的药物组合物及其医药用途
EP4493556A4 (en) 2022-03-15 2026-03-18 Zomagen Biosciences Ltd NLRP3 MODULATORS
KR20250005125A (ko) 2022-03-25 2025-01-09 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
EP4499646A4 (en) 2022-03-31 2026-03-18 Hangzhou Highlightll Pharmaceutical Co Ltd NLRP3 Inflammasome Inhibitors
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
CN116969920A (zh) 2022-04-29 2023-10-31 上海辉启生物医药科技有限公司 稠合哒嗪衍生物及其制备方法与医药用途
CA3251149A1 (en) 2022-05-13 2023-11-16 Neumora Therapeutics, Inc. NLRP3 INFLAMMASOME MODULATORS, ASSOCIATED PRODUCTS AND PROCESSES
WO2023232917A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Novel compounds
WO2024006559A1 (en) 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
WO2024012551A1 (zh) 2022-07-14 2024-01-18 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
JP2025523930A (ja) 2022-07-21 2025-07-25 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024033845A1 (en) 2022-08-10 2024-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN116789674B (zh) 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
CN119907797A (zh) 2022-09-23 2025-04-29 默沙东有限责任公司 用作nod样受体蛋白3抑制剂的酞嗪衍生物
CN120152974A (zh) 2022-10-26 2025-06-13 天维生物制药有限公司 缩环哒嗪衍生物
EP4612150A1 (en) 2022-10-31 2025-09-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024097598A1 (en) 2022-11-02 2024-05-10 Merck Sharp & Dohme Llc Triazines useful as inhibitors of nod-like receptor protein 3
US20260167637A1 (en) 2022-11-04 2026-06-18 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and use thereof
WO2024094150A1 (en) 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
JP2025537237A (ja) 2022-11-09 2025-11-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体
WO2024099993A1 (en) 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
AU2023376398A1 (en) 2022-11-09 2025-02-13 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
CN118056822A (zh) 2022-11-18 2024-05-21 正大天晴药业集团股份有限公司 一种哒嗪并环化合物及其用途
WO2024109922A1 (zh) 2022-11-25 2024-05-30 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
JP2025540202A (ja) 2022-12-07 2025-12-11 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３阻害のモジュレーターとしての新規化合物
WO2024121184A1 (en) 2022-12-08 2024-06-13 F. Hoffmann-La Roche Ag Inhibitors of nlrp3
EP4637746A1 (en) 2022-12-19 2025-10-29 Merck Sharp & Dohme LLC 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2024138045A1 (en) 2022-12-23 2024-06-27 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
CN120379995A (zh) 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
US20260200914A1 (en) 2022-12-28 2026-07-16 Astrazeneca Ab Nlrp3 inflammasome inhibitors
CN120418236A (zh) 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
EP4642784A1 (en) 2022-12-30 2025-11-05 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds as inhibitors of nlrp3
CN120813345A (zh) 2023-01-03 2025-10-17 科达制药 作为nlrp3抑制剂的有机化合物
WO2024160692A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
JP2026504422A (ja) 2023-01-31 2026-02-05 ヤンセン ファーマシューティカ エヌ．ベー． ＮＬＲＰ３阻害剤としてのピロロ［１，２－ｄ］［１，２，４］トリアジン及びピラゾロ［１，５－ｄ］［１，２，４］トリアジン
EP4658649A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV [1,2,4]triazolo[4,3-a]pyridines and [1,2,4]triazolo[4,3-a]pyrazines as nlrp3 inhibitors
EP4658644A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV 2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors
WO2024160693A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors

Also Published As

Publication number Publication date
PE20240765A1 (es) 2024-04-17
US20240199606A1 (en) 2024-06-20
US12312350B2 (en) 2025-05-27
EP4537900A2 (en) 2025-04-16
EP4320102C0 (en) 2026-01-14
AU2023263450B2 (en) 2025-04-17
CL2023002973A1 (es) 2024-03-08
CA3214676A1 (en) 2022-10-13
MA64053B1 (fr) 2026-02-27
JP2024050527A (ja) 2024-04-10
KR20230167394A (ko) 2023-12-08
JP2024514837A (ja) 2024-04-03
EP4331668A3 (en) 2024-06-05
US20240368160A1 (en) 2024-11-07
US11319319B1 (en) 2022-05-03
US20220340567A1 (en) 2022-10-27
AU2023263450C1 (en) 2025-10-30
US20260152500A1 (en) 2026-06-04
BR112023020483A2 (pt) 2023-11-21
US20240174668A1 (en) 2024-05-30
US20240158396A1 (en) 2024-05-16
IL307303A (en) 2023-11-01
US12281112B2 (en) 2025-04-22
AU2022256052A1 (en) 2023-11-16
JP7620120B2 (ja) 2025-01-22
MX2024000820A (es) 2024-02-06
AU2022256052B2 (en) 2025-06-05
WO2022216971A1 (en) 2022-10-13
US20230159526A1 (en) 2023-05-25
EP4331668A2 (en) 2024-03-06
TW202613116A (zh) 2026-04-01
US20250250270A1 (en) 2025-08-07
US12410167B2 (en) 2025-09-09
US20240360129A1 (en) 2024-10-31
TW202304905A (zh) 2023-02-01
US12351578B2 (en) 2025-07-08
EP4320102B1 (en) 2026-01-14
US12441728B2 (en) 2025-10-14
WO2022216971A9 (en) 2022-12-08
CN117510495A (zh) 2024-02-06
TWI909104B (zh) 2025-12-21
EP4537900A3 (en) 2025-07-16
HRP20260190T1 (hr) 2026-05-08
IL308378A (en) 2024-01-01
AU2025213656A1 (en) 2025-08-28
UA130929C2 (uk) 2026-06-17
TW202330522A (zh) 2023-08-01
AU2023263450A1 (en) 2023-11-23
JOP20230241A1 (ar) 2023-10-05
CL2024001964A1 (es) 2024-12-06
RS67854B1 (sr) 2026-03-31
US20260042757A1 (en) 2026-02-12
CN117500792A (zh) 2024-02-02
US20240360128A1 (en) 2024-10-31
CO2023013356A2 (es) 2023-10-30
MX2023011576A (es) 2023-11-09
ES3064060T3 (en) 2026-04-22
EP4320102A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
RS67854B1 (sr) Piridazinska jedinjenja za inhibiranje nlrp3
IL316450A (en) Compounds for inhibiting KIF18A
GB202008201D0 (en) Inhibitor compounds
GB201914860D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
GB202200735D0 (en) Compounds
GB202004960D0 (en) Inhibitor compounds
IL288292A (en) Oxathiazine compounds for gapdh inhibition
GB202208643D0 (en) Compounds
GB202110373D0 (en) Inhibitor compounds
GB201905328D0 (en) Inhibitor compounds
GB202307924D0 (en) Inhibitor compounds
GB202300881D0 (en) Inhibitor compounds
GB202208151D0 (en) Compounds
GB202315106D0 (en) PARP1 inhibitor compounds
GB202315093D0 (en) PARP1 inhibitor compounds
HK40101148A (en) Pyridazine compounds for inhibiting nlrp3
GB202117224D0 (en) Inhibitor compounds
GB202012969D0 (en) Inhibitor compounds
GB202201996D0 (en) Compounds
CA3307293A1 (en) Compounds for inhibiting amanzi
GB202112240D0 (en) Inhibitor compounds
GB202107325D0 (en) Inhibitor compounds
GB202104781D0 (en) Inhibitor compounds
GB202016964D0 (en) Inhibitor compounds